Galapagos

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 7-10 December 2024.

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos NV (NASDAQ:GLPG ) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ET Company Participants Sofie Van Gijsel - Head of IR Paul Stoffels - Chair of the Board & CEO Thad Huston - CFO & COO Jeevan Shetty - Head of Development Oncology Wulf Bocher - Head Immunology Therapeutic Area Conference Call Participants Xian Deng - UBS Judah Frommer - Morgan Stanley Alexander Kelly - TD Cowen Shan Hama - Jefferies Nevin Varghese - RBC Capital Markets Jacob Mekhael - KBC Securities Faisal Khurshid - Leerink Partners Sebastiaan Van der Schoot - VLK Operator Good day, and thank you for standing by. Welcome to the Galapagos Q3 2024 Financial Results Audio Webcast.

Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript

Webcast presentation   on   October 31, 2024,   at 1 3 :00 CET   /   8:00 am ET,   www.glpg.com

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024.

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

SAN DIEGO--(BUSINESS WIRE)--Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO) member of Blood Centers of America (BCA), today announced that it has been selected to manufacture Galapagos' CAR-T cell therapy candidate, GLPG5101, for its recently FDA cleared ATALANTA-1 clinical study in patients with relapsed/refractory non-Hodgkin lymphoma in the U.S. Galapagos (Euronext & Nasdaq: GLPG) is a clinical stage biotechnology company with operations in Europe.

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.

Galapagos receives transparency notification from EcoR1 Capital

Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.

Galapagos receives transparency notification from FMR LLC

Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.

Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats

Galapagos NV achieved positive results from its European phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL; phase 1 portion with 87.5% ORR and phase 2 portion with 93.3% ORR. The global non-Hodgkin Lymphoma market is expected to reach $16 billion by 2029; on average, between 30% to 40% of NHL patients have relapsed/refractory disease. IND clearance of U.S. phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL achieved; this trial could speed up enrollment and further establish efficacy with newly added patients.

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos' Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Galapagos NV (NASDAQ:GLPG ) Q2 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Sofie Van Gijsel - Head of Investor Relations Paul Stoffels - Chair of the Board and Chief Executive Officer Thad Huston - Chief Financial Officer and Chief Operating Officer Jeevan Shetty - Head of Development Oncology Conference Call Participants Brian Abrahams - RBC Capital Markets Philip Nadeau - TD Cowen Judah Frommer - Morgan Stanley Jason Gerberry - Bank of America Sean McCutcheon - Raymond James Jacob Mekhael - KBC Securities Operator Good day and thank you for standing by. Welcome to the Galapagos First Half 2024 Financial Results Conference Call.

Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript

BridGene Eligible to Receive Up to $15 9 Million in Total Payments SAN JOSE, Calif. , Aug. 1, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, today announced an expansion to its strategic collaboration and licensing agreement with Galapagos NV (Euronext: GLPG) (NASDAQ: GLPG).

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Webcast presentation   with management on   2   August 2024,   at 14:00 CET   /   8:00 AM ET,   www.glpg.com

Galapagos reports half-year 2024 financial results and provides second quarter business update

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress. Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform.

Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

Adaptimmune Therapeutics

Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications Adaptimmune will hold a conference call tomorrow (May 31 st ) at 8 a.m. EDT (webcast link here and more details below) Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 30, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), and Galapagos NV (NA: GLPG) (NASDAQ: GLPG) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries.

Galapagos creates new subscription right plans

Mechelen, Belgium; 15 May 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Blood Centers of America (BCA) today announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos' CAR-T cell therapies through BCA's network in the U.S.

Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.

Galapagos NV (NASDAQ:GLPG ) Q1 2024 Results Conference Call May 3, 2024 8:00 AM ET Company Participants Sofie Van Gijsel - Investor Relations Paul Stoffels - Chief Executive Officer Thad Huston - Chief Financial Officer and Chief Operating Officer Jeevan Shetty - Head of Development Oncology Conference Call Participants Xian Deng - UBS Philip Nadeau - TD Cowen Nevin Varghese - RBC Capital Markets Judah Frommer - Morgan Stanley Jason Gerberry - Bank of America Jacob Mekhael - KBC Securities Sean McCutcheon - Raymond James Sebastiaan van der Schoot - VLK Shan Hama - Jefferies Sofie Van Gijsel Welcome all to the audio webcast of Galapagos' Q1 2024 Results. I'm Sofie Van Gijsel, Investor Relations representing the reporting team at Galapagos.

Galapagos NV (GLPG) Q1 2024 Earnings Call Transcript

Webcast presentation   with management on  3  May 2024,   at 14:00 CET   /   8:00 am ET,   www.glpg.com

Galapagos reports first quarter 2024 financial results

Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 30 April 2024 were approved.

Galapagos' shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -9.97% in 4 Weeks, Here's Why You Should You Buy the Dip in Galapagos (GLPG)

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)

News for Galapagos Stock (GLPG)